American Shared Hospital Services Shares News That Mevion Medical Systems Has Received FDA 510(k) Clearance For Its MEVION S250 Proton Therapy System

AMERICAN SHARED HOSPITAL SERVICES (AMEX:AMS), a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today shared a recent announcement from Mevion Medical Systems, Inc. regarding Mevion Medical Systems' receipt of FDA 510(k) clearance for its MEVION S250 Proton Therapy System.

"The Mevion team has created a truly revolutionary medical therapy device. Revolutionary in the sense that this machine combines the elements of a superconducting synchrocyclotron mounted on a gantry that is less expensive than all other proton therapy devices, using accelerator technology that has been proven to be reliable and simple for the user," said AMS Chairman and Chief Executive Officer Ernest A. Bates, M.D.

"This is an exciting day for Mevion, for AMS, and for cancer patients and clinicians worldwide. The MEVION S250 significantly reduces the cost, size and complexity of proton technology, and promises to bring accessibility, affordability and practicality to this innovative therapy. With FDA 510(k) clearance for the MEVION S250 now in hand, we expect AMS' proton therapy business to accelerate, both the projects we have already announced as well as additional projects that have awaited the FDA's positive decision," said Craig K. Tagawa, Chief Operating Officer of AMS.

AMS owns approximately 1% of Mevion, and is developing proton therapy centers in Orlando, Boston and Long Beach, California which are expected to employ the MEVION S250 proton therapy device:

Mevion Medical Systems Announces FDA 510(k) Clearance for the MEVION S250 Proton Therapy System

MEVION S250 patented technology significantly reduces the cost of implementing and operating proton therapy centers.

LITTLETON, MA., June 11, 2012 -- Mevion Medical Systems, Inc., a radiation therapy company dedicated to advancing the treatment of cancer, announced today that it has received FDA 510(k) clearance for its MEVION S250 Proton Therapy System. The MEVION S250 is a first-of-its-kind proton/therapy system that provides the same precise, non-invasive treatment advantages and capabilities of complex, large, and costly proton therapy systems but with higher patient throughput, a significantly reduced footprint, improved reliability, and lower implementation and operational costs. The MEVION S250 delivers precise and intense proton beams that physicians can use to treat tumors and lesions or any other condition where radiotherapy is indicated.

If you liked this article you might like

European Stocks Mixed After Earnings Reports as Pound Plunges

Analysts' Actions -- eBay, Fitbit, Texas Roadhouse and More

American Shared Hospital Services Stock Downgraded (AMS)

Cramer's 'Mad Money' Recap: Hi-Yo Silver!

Cramer's 'Mad Money' Recap: Hi-Yo Silver!

Health Stocks in Motion

Health Stocks in Motion